Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,599.96
(
0.00%
)
US TECH 100
29,691.60
(
-0.06%
)
Dow Jones
51,078.88
(
0.00%
)
Brent Oil
93.43
(
-2.65%
)
Bitcoin
69,103.00
(
-3.17%
)
News Focus
News Focus
Post# of 828683
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

flipper44

Send PM Follow Ignore
Followers 309
Posts 37502
Boards Moderated 1
Alias Born 11/14/2013

flipper44

Member Level

Re: pgsd post# 653879

Thursday, 12/07/2023 6:21:08 AM

Thursday, December 07, 2023 6:21:08 AM

Post# of 828683

The median OS for vibostolimab/pembrolizumab plus docetaxel was 10.2 months (95% CI, 8.6-14.9),

7.5 months (95% CI, 5.2-13.4) for vibostolimab/pembrolizumab alone

and 8.8 months (95% CI, 6.4-11.1) for docetaxel.



These results did not reach statistical significance. (Metastatic non-small cell lung cancer)
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News